Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer

Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer

BackgroundBladder cancer (BC) is the most common tumor of the urinary system. Non-muscle-invasive bladder cancer (NMIBC) has a high recurrence rate after surgery, and patients with muscle-invasive bladder cancer (MIBC) have poor quality of life after radical surgery. Understanding the molecular mech...

Full description

Bibliographic Details
Main Authors:	WenBo Wu, GaoZhen Jia, Lei Chen, HaiTao Liu, ShuJie Xia
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Genetics
Subjects:	annexin NMIBC MIBC prognosis public databases
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2021.731625/full

Similar Items

Novel Ferroptosis-Related Multigene Prognostic Models for Patients with Bladder Cancer
by: Zhang S, et al.
Published: (2021-11-01)

Interobserver agreement for the Vesical Imaging-Reporting and Data System (VI-RADS) in differentiating non-muscle-invasive and muscle-invasive urinary bladder tumors
by: Noha M. Taha, et al.
Published: (2023-12-01)

The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M
by: Jian-Xuan Sun, et al.
Published: (2023-06-01)

Inhibition of FGFR3 upregulates MHC‐I and PD‐L1 via TLR3/NF‐kB pathway in muscle‐invasive bladder cancer
by: WenBo Wu, et al.
Published: (2023-07-01)

Pilot study on quantifying the epithelial/mesenchymal hybrid state in the non-muscle invasive and muscle invasive bladder tumors: A promising marker of diagnosis and prognosis
by: Rinni Singh, et al.
Published: (2023-12-01)

Mapping the tumor microenvironment in bladder cancer and exploring the prognostic genes by single-cell RNA sequencing
by: Zhibin Chen, et al.
Published: (2023-01-01)

Editorial: Recent advances in the treatment of upper urinary tract bladder cancers
by: Łukasz Zapała, et al.
Published: (2023-10-01)

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
by: Sikic D, et al.
Published: (2021-08-01)

Lymphocyte to Monocyte Ratio: A New Independent Prognostic Factor in Bladder Cancer Progression?
by: Matteo Ferro, et al.
Published: (2021-09-01)

Identification of hub genes in bladder cancer based on weighted gene co‐expression network analysis from TCGA database
by: Lei Wang, et al.
Published: (2022-09-01)

Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis
by: Mario Pones, et al.
Published: (2021-05-01)

Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature
by: Hua-Ping Liu, et al.
Published: (2023-03-01)

A novel nomogram based on body composition and nutritional indicators to predict the prognosis of patients with muscle‐invasive bladder cancer undergoing radical cystectomy
by: Xin Zhong, et al.
Published: (2023-12-01)

Single dose Tadalafil 5 mg in Muscle Invasive Bladder Cancer (MIBC) patient induce priapism: A case report and literature review
by: Diaswara Prabharani, et al.
Published: (2022-11-01)

Potential prognostic and therapeutic value of ANXA8 in renal cell carcinoma: based on the comprehensive analysis of annexins family
by: Li-Hui Wang, et al.
Published: (2023-07-01)

Research Progress in Risk Stratification Tools and Prognostic Models for Non-muscle-invasive Bladder Cancer
by: ZHAO Jiahong, et al.
Published: (2020-04-01)

A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer
by: Zhijie Xu, et al.
Published: (2021-02-01)

Apoptosis, annexin A5 and anti-annexin A5 antibodies in the antiphospholipid syndrome
by: Bećarević Mirjana, et al.
Published: (2013-01-01)

Upregulated expression of Annexin II is a prognostic marker for patients with gastric cancer
by: Zhang Qi, et al.
Published: (2012-06-01)

Identification and Validation of an Annexin-Related Prognostic Signature and Therapeutic Targets for Bladder Cancer: Integrative Analysis
by: Xitong Yao, et al.
Published: (2022-02-01)

The Significance of Neutrophil-to-Lymphocyte Ratio and Combined Chemoradiotherapy in Patients Undergoing Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
by: Wu CT, et al.
Published: (2020-12-01)

A cohort profile of the Graham Roberts study cohort
by: Beth Russell, et al.
Published: (2024-01-01)

Comment on “Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma”
by: Gopal Sharma
Published: (2021-08-01)

Response to comment on “Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma”
by: Yu-Fei Xie, et al.
Published: (2022-09-01)

Research progress on the mechanism of annexin A family members in breast cancer
by: NAN Lu, GUO Menjie, GAO Yanan, JIA Hongyan
Published: (2024-03-01)

Overexpression of KMT9α Is Associated with Aggressive Basal-like Muscle-Invasive Bladder Cancer
by: Florestan J. Koll, et al.
Published: (2023-02-01)

Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancer
by: Michiel Vlaming, et al.
Published: (2020-01-01)

TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting
by: Rosario Leonardi, et al.
Published: (2023-02-01)

Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins
by: Rui Gou, et al.
Published: (2019-09-01)

Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer
by: Nada Humayun-Zakaria, et al.
Published: (2019-03-01)

The Bladder Microbiome Is Associated with Epithelial–Mesenchymal Transition in Muscle Invasive Urothelial Bladder Carcinoma
by: Wei Tse Li, et al.
Published: (2021-07-01)

How long should we follow patients managed for muscle-invasive bladder cancer? Lesson learned from a recent clinical practice
by: Aldo Franco De Rose, et al.
Published: (2022-09-01)

BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine
by: Omodele Ashiru, et al.
Published: (2019-07-01)

Cost‑effectiveness analysis of hexaminolevulinate (Hexvix®) guided cystoscopy in Non‑Muscle Invasive Bladder Cancer patients (NMIBC) in Italy
by: Craig Bennison, et al.
Published: (2014-09-01)

Misinterpretation resulting in a diagnosis of bladder cancer – A case emphasising the value of diagnostic reconsideration
by: Kira Thorsteinsson, et al.
Published: (2022-01-01)

Expression of protease activating receptor-2 (PAR-2) is positively correlated with the recurrence of non-muscle invasive bladder cancer: an immunohistochemical analysis
by: Nakahara K, et al.
Published: (2019-04-01)

Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy
by: Elisabet Cantó, et al.
Published: (2021-08-01)

Identification of The Immune Subtype Among Muscle-invasive Bladder Cancer Patients by Multiple Datasets
by: Khyber Shinwari, et al.
Published: (2022-01-01)

Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence
by: Tian-Wei Wang, et al.
Published: (2019-10-01)

Preoperative systemic immune‐inflammation index as a significant prognostic factor after TURBT in patients with non‐muscle‐invasive bladder cancer: A retrospective study based on propensity score matching analysis
by: Li Ding, et al.
Published: (2023-03-01)